US Corporate Board Director Changes SEC Filings — July 10, 2026
The July 10, 2026, board room change digest reveals a period of significant leadership transition across 32 US-listed companies, with a notable concentration of CFO and C-suite departures and appointments. The most critical development is the severe financial distress at **ZyVersa Therapeutics**, where a director resigned and management is considering going dark, divesting assets, and cutting headcount. Conversely, **Ategrity Specialty Insurance** provides a strong counterpoint, pre-announcing record Q2 results with >22% premium growth and >75% net income growth, alongside a CFO transition. A pattern of planned retirements and transitions is evident at **Adient**, **Sterling Infrastructure**, and **Lee Enterprises**, while companies like **KBR** and **Team Inc.** are proactively adjusting executive severance policies. The data shows a mix of routine board refreshment (e.g., **Alpha & Omega**, **Axon Enterprise**) and more disruptive changes, such as the sudden resignation of **Lands' End's** top legal and licensing executive. Overall, the period is characterized by high leadership fluidity, with a few filings signaling deep operational or financial challenges that warrant close monitoring.